Healthcare
Nurix Therapeutics, Inc.(NRIX)
Live Price
Offline$17.55
+2.51% today
1Y Change
+66.09%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $1.46B
- Revenue Growth
- +54.0%
- EPS Growth
- -5.9%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nurix Therapeutics, Inc. (NRIX) is a Healthcare stock with a market cap of $1.46B and listed on NASDAQ. The stock last traded around $17.55 and up 66.1% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +54.0%, EPS growth of -5.9%, a dividend yield of 0.0%. What stands out right now is revenue +54.0%, EPS -5.9%, free cash flow -44.9% with operating margin -439.3% and ROIC -57.6%. Valuation already assumes a fairly strong business story at price/sales 20.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NRIX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+54.0% vs +7.6% peer median
Operating Margin
Below sector median
-439.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +54.0% and EPS is at -5.9%, with operating margin around -439.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 14, 2026 | โ | +4.1% | +0.9% | -2.1% |
2026 Jan 28, 2026 | +2.4% | -1.6% | -7.4% | -9.8% |
2025 Oct 9, 2025 | -22.6% | -10.1% | -7.6% | +15.3% |
Benchmark Edge
NRIX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NRIX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NRIX Max Drawdown
-37.48%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NRIX and SPY.
Company Overview
Nurix Therapeutics, Inc.
NASDAQ Global Market
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
- Leadership
- Arthur T. Sands
- IPO Date
- Jul 24, 2020
- Employees
- 286
- Street Address
- 1700 Owens Street
- Mailing
- San Francisco, CA, 94158
- Region
- San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 415 660 5320
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 20.3
- Price/Book
- 3.8
Growth
- Revenue
- +54.0%
- EPS
- -5.9%
- Free Cash Flow
- -44.9%
Profitability
- Gross Margin
- -139.4%
- Operating Margin
- -439.3%
- Net Margin
- -411.4%
- ROE
- -64.2%
- ROIC
- -57.6%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 6.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.